Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P900056/S226

ROTAPRO Rotational Atherectomy Systems

Boston Scientific Corp · Decision date Oct 21, 2026

MEDTECHLEDGER EXPLANATIONP900056/S226

What did the FDA approve?

The FDA record cited here describes a real-time process supplement for the ROTAPRO rotational atherectomy system, identified as P900056/S226 and dated 2026-10-21. The reported scope is a design change to a component of the Pneumatic Kit used with the ROTAPRO console. The supplement category is change in design, components, specifications or material, filed under product code MCX for a coronary atherectomy catheter.

The identifier ties the action to the existing P900056 approval and its applicant, Boston Scientific Corp. This is a supplement rather than a new approval of the whole system, and the record does not describe the component, the nature of the design change, or any safety or effectiveness determination. The source does not state that clinical data were reviewed, so the decision should not be read as independent proof of clinical benefit.

The record gives no detail on which Pneumatic Kit component changed or how. That information is absent.

FDA approval order statement

a design change to a component of the Pneumatic Kit for the ROTAPRO console
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Oct 21, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P900056/S226
Regulatory pathway
PMA supplement
Product code
MCX
Decision code
APPR
Decision date
Oct 21, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: CATHETER, CORONARY, ATHERECTOMY.

Product code
MCX
FDA device class
3

For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P900056/S221 · Related supplement

    ROTABLATOR Rotational Atherectomy System

  2. P900056/S222 · Related supplement

    ROTAPRO Rotational Atherectomy System

  3. P900056/S223 · Related supplement

    ROTAPRO Rotational Atherectomy System

  4. P900056/S224 · Related supplement

    Rotablator; ROTAPRO Rotational Atherectomy Systems

  5. P900056/S225 · Related supplement

    ROTABLATOR Rotational Atherectomy System

  6. P900056/S226 received

    Application receipt date recorded by FDA.

  7. P900056/S228 · Related supplement

    ROTAPRO Rotational Atherectomy System

  8. P900056/S229 · Related supplement

    ROTAPRO Rotational Atherectomy System

  9. P900056/S226 · FDA decision

    Real-Time Process

Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P900056

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalMay 28, 1993FDA
Boston Scientific CorpPMA supplementAug 14, 2025FDA
Boston Scientific CorpPMA supplementOct 27, 2025FDA
Boston Scientific CorpPMA supplementMar 5, 2026FDA
Boston Scientific CorpPMA supplementApr 9, 2026FDA
Boston Scientific CorpPMA supplementMay 6, 2026FDA
Boston Scientific CorpPMA supplementOct 20, 2026FDA
Boston Scientific CorpPMA supplementOct 21, 2026FDA

Explore the linked device profile

Other records with product code MCX

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
Two Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records